CATALYST PHARMACEUTICALS, INC. 4

President and CEO Richard J. Daly had 271,266 common shares, 2,438,947 option shares, and 281,612 RSUs in Catalyst Pharmaceuticals, Inc. cashed out or cancelled for cash at a $31.50 per-share merger price on July 15, 2026.

On July 15, 2026, in connection with the cash acquisition of Catalyst Pharmaceuticals, Inc. by Angelini Pharma S.p.A. at $31.50 per share, President and CEO Richard J. Daly disposed of all his equity-based awards. A total of 271,266 shares of common stock were converted into cash at $31.50 per share (about $8.54 million). In addition, multiple tranches of vested stock options with exercise prices ranging from $4.64 to $22.77 per share and expirations from 2026 to 2032, covering an aggregate 2,438,947 option shares, were cancelled and converted into cash equal to the intrinsic value per share (the spread between $31.50 and the exercise price) multiplied by the number of shares underlying each option grant. Daly also held several blocks of restricted stock units (RSUs) totaling 281,612 shares that vested in full upon closing and were likewise cancelled in exchange for cash equal to $31.50 per unit. Following these merger-triggered cash-outs, Daly no longer beneficially owns Catalyst equity, and the transactions represent change-of-control consideration rather than discretionary open-market trading.

Filing Facts

CIK

1369568

Ticker

CPRX

Form

4

Source Type

fda

Accession

0001161697-26-000173

Alert Tier

7